|  |
| --- |
| **Table A1: Patient Baseline Characteristics, Unmatched, Favorable Risk, Black men vs White men** |
| Variable |  | Black | White | P-value | SMD |
|  |  |  |  |  |  |
|  |  | 6229 | 39326 |  |  |
| Age, mean (SD), years |  | 60.53 (7.83) | 62.84 (7.67) | <0.001 | 0.299 |
| Treatment | BT | 992 (15.9) | 5171 (13.1) | <0.001 | 0.177 |
|  | EBRT alone | 1140 (18.3) | 5194 (13.2) |  |  |
|  | RP alone | 2145 (34.4) | 14836 (37.7) |  |  |
|  | RP and PLND | 1952 (31.3) | 14125 (35.9) |  |  |
| Facility type | Community Cancer Program | 436 (7.0) | 2519 (6.4) | <0.001 | 0.216 |
|  | Comprehensive Community Cancer Program | 2158 (34.6) | 17626 (44.8) |  |  |
|  | Academic/Research Program | 2735 (43.9) | 14992 (38.1) |  |  |
|  | Integrated Network Cancer Program | 892 (14.3) | 4159 (10.6) |  |  |
|  | unknown | 8 (0.1) | 30 (0.1) |  |  |
| geography | New England | 164 (2.6) | 2220 (5.6) | <0.001 | 0.675 |
|  | Middle Atlantic | 957 (15.4) | 5720 (14.5) |  |  |
|  | South Atlantic | 2463 (39.5) | 7738 (19.7) |  |  |
|  | East North Central | 999 (16.0) | 7195 (18.3) |  |  |
|  | East South Central | 692 (11.1) | 3151 (8.0) |  |  |
|  | West North Central | 175 (2.8) | 4020 (10.2) |  |  |
|  | West South Central | 424 (6.8) | 1896 (4.8) |  |  |
|  | Mountain | 42 (0.7) | 1931 (4.9) |  |  |
|  | Pacific | 305 (4.9) | 5425 (13.8) |  |  |
|  | unknown | 8 (0.1) | 30 (0.1) |  |  |
| insurance | No insurance | 161 (2.6) | 429 (1.1) | <0.001 | 0.306 |
|  | Private Insurance | 3409 (54.7) | 22623 (57.5) |  |  |
|  | Medicaid | 358 (5.7) | 462 (1.2) |  |  |
|  | Medicare | 2019 (32.4) | 14775 (37.6) |  |  |
|  | Other Government | 184 (3.0) | 642 (1.6) |  |  |
|  | unknown | 98 (1.6) | 395 (1.0) |  |  |
| income | $38,000 - $47,999 | 1413 (22.7) | 8167 (20.8) | <0.001 | 0.725 |
|  | $48,000 - $62,999 | 1247 (20.0) | 11193 (28.5) |  |  |
|  | $63,000 + | 1206 (19.4) | 15572 (39.6) |  |  |
|  | < $38,000 | 2349 (37.7) | 4299 (10.9) |  |  |
|  | unknown | 14 (0.2) | 95 (0.2) |  |  |
| Charleson Deyo comorbidity index | 0 | 4958 (79.6) | 33315 (84.7) | <0.001 | 0.137 |
|  | 1 | 1086 (17.4) | 5276 (13.4) |  |  |
|  | 2+ | 185 (3.0) | 735 (1.9) |  |  |
|  |  | 60.53 (7.83) | 62.84 (7.67) | <0.001 | 0.299 |
| risk  | favorable intermediate | 2866 (46.0) | 16603 (42.2) | <0.001 | 0.076 |
|  | Low | 3363 (54.0) | 22723 (57.8) |  |  |
| Diagnosis to treatment initiation time | 0-90 | 3064 (50.9) | 23027 (60.9) | <0.001 | 0.209 |
|  | >90 | 2669 (44.3) | 12988 (34.3) |  |  |
|  | unknown | 290 (4.8) | 1797 (4.8) |  |  |
| clinical T stage | T1 | 5230 (84.0) | 30936 (78.7) | <0.001 | 0.137 |
|  | T2 | 998 (16.0) | 8388 (21.3) |  |  |
|  | unknown | 1 (0.0) | 2 (0.0) |  |  |
| clinical Gleason score | <=6 | 3635 (58.4) | 24520 (62.4) | <0.001 | 0.082 |
|  | 7 | 2594 (41.6) | 14806 (37.6) |  |  |
| PSA | <10 | 5785 (92.9) | 37700 (95.9) | <0.001 | 0.13 |
|  | 10-20 | 444 (7.1) | 1626 (4.1) |  |  |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; PLND=pelvic lymph node dissection; SMD=Standardized mean difference; CI=Confidence Interval; fIR=favorable intermediate risk; LR=low risk; AfA=African American; Cc=Caucasian* |
| \*ng/ml  |
| \*\*combined gleason score |